Abstract 4363216: RUNX2, IBSP, and SPP1 as Key Molecular Nodes in Calcific Aortic Stenosis: Transcriptomic Diagnostics and Emerging Therapeutic Targets.

Calcific aortic stenosis (CAS) is the most common valvular disease in the elderly, with no approved pharmacological treatment to slow or reverse its progression. This study combined a systematic literature review (38 human-only studies, PRISMA criteria) with transcriptomic analysis of publicly available datasets (GSE51472 and GSE12644), including 35 human aortic valve samples (15 control, 15 calcified, 5 sclerotic). Differential expression was assessed using the Limma package, applying FDR correction (padj < 0.01) and fold change threshold (|FC| ≥ 1). Key genes were identified based on significant overexpression and biological relevance. RUNX2, IBSP, and SPP1 emerged as central regulators linked to osteogenic transdifferentiation, immune modulation, and extracellular matrix remodeling. KEGG pathway analysis showed enrichment in ECM-receptor interaction, PI3K-Akt signaling. Coexpression and protein-protein interaction networks revealed strong functional clustering of these genes. ROC curve analysis yielded high diagnostic performance: AUC values were 0.79 (RUNX2), 0.65 (IBSP), and 0.75 (SPP1), indicating robust classification of diseased versus normal tissue. Expression levels rose progressively across control, calcified, and sclerotic valve samples. Drug repurposing candidates were identified targeting these molecules. MEK inhibitors (trametinib, selumetinib) downregulate RUNX2 via MAPK/ERK pathway inhibition. Epigenetic modulators (vorinostat, valproic acid) could suppress RUNX2 transcriptionally. The integrin antagonist cilengitide blocks αvβ3, disrupting IBSP/SPP1-mediated signaling. While these agents are approved for oncology or neurology, their utility in valve calcification remains investigational. In summary, this study highlights RUNX2, IBSP, and SPP1 as transcriptomic biomarkers and actionable therapeutic targets in CAS. Their expression profiles, biological roles, and druggability make them high-priority candidates for future diagnostic tools and targeted interventions in a disease currently reliant on surgical replacement.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4363216
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4363216: RUNX2, IBSP, and SPP1 as Key Molecular Nodes in Calcific Aortic Stenosis: Transcriptomic Diagnostics and Emerging Therapeutic Targets.

Isabel Barragán
Circulation
Cardiac Valve Diseases and Treatments
article

Abstract 4363216: RUNX2, IBSP, and SPP1 as Key Molecular Nodes in Calcific Aortic Stenosis: Transcriptomic Diagnostics and Emerging Therapeutic Targets.

Isabel Barragán
article en

Abstract

Calcific aortic stenosis (CAS) is the most common valvular disease in the elderly, with no approved pharmacological treatment to slow or reverse its progression. This study combined a systematic literature review (38 human-only studies, PRISMA criteria) with transcriptomic analysis of publicly available datasets (GSE51472 and GSE12644), including 35 human aortic valve samples (15 control, 15 calcified, 5 sclerotic). Differential expression was assessed using the Limma package, applying FDR correction (padj < 0.01) and fold change threshold (|FC| ≥ 1). Key genes were identified based on significant overexpression and biological relevance. RUNX2, IBSP, and SPP1 emerged as central regulators linked to osteogenic transdifferentiation, immune modulation, and extracellular matrix remodeling. KEGG pathway analysis showed enrichment in ECM-receptor interaction, PI3K-Akt signaling. Coexpression and protein-protein interaction networks revealed strong functional clustering of these genes. ROC curve analysis yielded high diagnostic performance: AUC values were 0.79 (RUNX2), 0.65 (IBSP), and 0.75 (SPP1), indicating robust classification of diseased versus normal tissue. Expression levels rose progressively across control, calcified, and sclerotic valve samples. Drug repurposing candidates were identified targeting these molecules. MEK inhibitors (trametinib, selumetinib) downregulate RUNX2 via MAPK/ERK pathway inhibition. Epigenetic modulators (vorinostat, valproic acid) could suppress RUNX2 transcriptionally. The integrin antagonist cilengitide blocks αvβ3, disrupting IBSP/SPP1-mediated signaling. While these agents are approved for oncology or neurology, their utility in valve calcification remains investigational. In summary, this study highlights RUNX2, IBSP, and SPP1 as transcriptomic biomarkers and actionable therapeutic targets in CAS. Their expression profiles, biological roles, and druggability make them high-priority candidates for future diagnostic tools and targeted interventions in a disease currently reliant on surgical replacement.

CirculationVol. 152(Suppl_3)
Instituto Politécnico Nacional (MX)
Openalex Percentile: Top 51%
Cardiac Valve Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.